Search results for Myostatin

Anti-MSTN/GDF8 Antibody (SAA2388), ProteoGenix, ARO-A22845

Efmitermant alfa Biosimilar – Anti-GDF-8 fusion protein – Research Grade, ProteoGenix, PX-TA2039

Description of Efmitermant alfa Biosimilar - Anti-GDF-8 fusion protein - Research Grade Efmitermant alfa Biosimilar: A Promising Antibody for Targeting GDF-8 Introduction Efmitermant alfa Biosimilar is a novel fusion protein that has gained significant attention in the field of biopharmaceuticals. It is a biosimilar of Efmitermant alfa, a recombinant protein used for the treatment of anemia associated with chronic kidney disease. This biosimilar is designed to target growth and differentiation factor 8 (GDF-8), a protein involved in regulating muscle growth and development. In this article, we will explore the structure, activity, and potential applications of Efmitermant alfa Biosimilar as a therapeutic antibody. Structure of Efmitermant alfa Biosimilar Efmitermant alfa Biosimilar is a fusion protein composed of two components: Efmitermant alfa and an anti-GDF-8 antibody. The Efmitermant alfa component is a glycosylated protein with a molecular weight of approximately 30 kDa. It is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. The anti-GDF-8 antibody component is a monoclonal antibody that specifically binds to GDF-8 with high affinity. It is a human IgG1 antibody with a molecular weight of approximately 150 kDa. The two components of Efmitermant alfa Biosimilar are linked together by a flexible linker peptide, resulting in a final molecular weight of approximately 180 kDa. This fusion protein has a similar structure to the native GDF-8 protein, allowing it to bind to GDF-8 with high specificity and potency. Mechanism of Action Efmitermant alfa Biosimilar exerts its therapeutic effects by inhibiting the activity of GDF-8. GDF-8 is a member of the transforming growth factor-beta (TGF-β) superfamily and plays a crucial role in regulating muscle growth and development. In healthy individuals, GDF-8 helps maintain muscle homeostasis by inhibiting muscle growth and promoting muscle atrophy. However, in certain disease conditions, such as cancer cachexia and muscular dystrophy, GDF-8 is overexpressed, leading to excessive muscle wasting. By binding to GDF-8, Efmitermant alfa Biosimilar blocks its interaction with its receptor, preventing the downstream signaling cascade that promotes muscle atrophy. This results in increased muscle mass and improved muscle function, making it a promising therapeutic target for various muscle-related disorders. Potential Applications Efmitermant alfa Biosimilar has shown promising results in preclinical studies for the treatment of various muscle-related disorders. In a mouse model of cancer cachexia, treatment with Efmitermant alfa Biosimilar resulted in increased muscle mass and improved muscle function. In a mouse model of muscular dystrophy, it improved muscle strength and reduced muscle degeneration. These results suggest that Efmitermant alfa Biosimilar could be a potential therapeutic option for these conditions. Furthermore, GDF-8 has also been implicated in other diseases, such as osteoporosis and type 2 diabetes. Inhibition of GDF-8 activity by Efmitermant alfa Biosimilar could potentially have beneficial effects in these diseases as well. Clinical trials are currently underway to evaluate the safety and efficacy of Efmitermant alfa Biosimilar in these conditions. Conclusion Efmitermant alfa Biosimilar is a novel fusion protein designed to target GDF-8, a protein involved in regulating muscle growth and development. Its unique structure and mechanism of action make it a promising therapeutic option for various muscle-related disorders. With ongoing research and clinical trials, Efmitermant alfa Biosimilar has the potential to improve the lives of patients suffering from these conditions.

Ramatercept Biosimilar – Anti-GDF-8 fusion protein – Research Grade, ProteoGenix, PX-TA2102

Description of Ramatercept Biosimilar - Anti-GDF-8 fusion protein - Research Grade Introduction Ramatercept Biosimilar is a novel anti-GDF-8 fusion protein that has gained significant attention in the field of biopharmaceutical research. This fusion protein is a biosimilar version of the original Ramatercept, which is a recombinant human protein developed by Acceleron Pharma Inc. It is designed to target and inhibit the activity of GDF-8, also known as myostatin, a protein that plays a crucial role in regulating muscle growth and development. In this scientific web content, we will discuss the structure, activity, and potential applications of Ramatercept Biosimilar as a therapeutic agent. Structure of Ramatercept Biosimilar Ramatercept Biosimilar is a fusion protein consisting of two components: the extracellular domain of the activin receptor type IIB (ActRIIB) and the Fc region of human immunoglobulin G1 (IgG1). The ActRIIB domain is responsible for binding to GDF-8, while the Fc region provides stability and prolongs the half-life of the fusion protein in the body. The ActRIIB domain of Ramatercept Biosimilar is identical to that of the original Ramatercept, with 368 amino acids. It has a molecular weight of approximately 40 kDa and is glycosylated, meaning it has sugar molecules attached to it. The Fc region, on the other hand, has 233 amino acids and a molecular weight of approximately 25 kDa. Activity of Ramatercept Biosimilar The primary function of Ramatercept Biosimilar is to inhibit the activity of GDF-8, a protein that negatively regulates muscle growth and development. GDF-8 is a member of the transforming growth factor-beta (TGF-β) superfamily and is primarily produced in skeletal muscle cells. It acts as a negative regulator of muscle mass by inhibiting the proliferation and differentiation of muscle cells. Ramatercept Biosimilar works by binding to GDF-8 and preventing its interaction with the ActRIIB receptor. This, in turn, leads to an increase in the activity of another TGF-β family member, myostatin-related gene (MSTN), which promotes muscle growth and development. By inhibiting GDF-8, Ramatercept Biosimilar can potentially increase muscle mass and strength, making it a promising therapeutic target in conditions associated with muscle wasting. Potential Applications of Ramatercept Biosimilar Ramatercept Biosimilar has shown promising results in preclinical and clinical studies as a potential therapeutic agent for various conditions associated with muscle wasting. These include muscular dystrophy, sarcopenia, cachexia, and muscle wasting in chronic diseases such as cancer and HIV. In a phase II clinical trial, Ramatercept Biosimilar was evaluated in patients with facioscapulohumeral muscular dystrophy (FSHD), a genetic disorder characterized by progressive muscle weakness and wasting. The results showed a significant increase in muscle mass and strength in patients treated with Ramatercept Biosimilar compared to the placebo group. In addition to its potential use in muscle-wasting conditions, Ramatercept Biosimilar has also shown promise in improving exercise capacity in patients with pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. In a phase II clinical trial, treatment with Ramatercept Biosimilar led to a significant improvement in the six-minute walk distance, a measure of exercise capacity, in patients with PAH. Conclusion In conclusion, Ramatercept Biosimilar is a novel anti-GDF-8 fusion protein with a unique structure and mechanism of action. It has the potential to be a promising therapeutic agent for various conditions associated with muscle wasting, including muscular dystrophy, sarcopenia, and cachexia. Further research and clinical trials are needed to fully understand the potential of Ramatercept Biosimilar and its role in the treatment of these conditions.

Taldefgrobep alfa Biosimilar – Anti-GDF-8 fusion protein – Research Grade, ProteoGenix, PX-TA2038

Description of Taldefgrobep alfa Biosimilar - Anti-GDF-8 fusion protein - Research Grade Introduction to Taldefgrobep alfa Biosimilar – Anti-GDF-8 fusion protein Taldefgrobep alfa Biosimilar, also known as Anti-GDF-8 fusion protein, is a novel biopharmaceutical that has shown promising results in pre-clinical studies as a potential therapeutic agent for various diseases. This fusion protein is a biosimilar of the well-known therapeutic antibody, Taldefgrobep alfa, which has been approved for the treatment of certain cancers. In this article, we will explore the structure, activity, and potential applications of Taldefgrobep alfa Biosimilar. Structure of Taldefgrobep alfa Biosimilar Taldefgrobep alfa Biosimilar is a fusion protein composed of two components – a monoclonal antibody and a growth differentiation factor 8 (GDF-8) inhibitor. The monoclonal antibody component is derived from Taldefgrobep alfa, while the GDF-8 inhibitor is a novel addition. This fusion protein is designed to specifically target GDF-8, a protein that plays a crucial role in cell growth and differentiation. The monoclonal antibody component of Taldefgrobep alfa Biosimilar is a fully humanized IgG1 antibody, which has been engineered to have a high affinity for GDF-8. This antibody binds to GDF-8 with high specificity, preventing its interaction with its receptors and inhibiting its activity. The GDF-8 inhibitor component is a small molecule that binds to GDF-8 and blocks its signaling pathway, further enhancing the inhibitory effect of the antibody. Activity of Taldefgrobep alfa Biosimilar The main activity of Taldefgrobep alfa Biosimilar is the inhibition of GDF-8, which has been implicated in various diseases such as cancer, muscle wasting, and fibrosis. By blocking the activity of GDF-8, this fusion protein has the potential to slow down or even reverse disease progression. In pre-clinical studies, Taldefgrobep alfa Biosimilar has shown promising results in inhibiting the growth of various cancer cell lines, including breast, lung, and prostate cancer. It has also been shown to reduce muscle wasting in animal models, making it a potential treatment for conditions such as cachexia and sarcopenia. Additionally, the GDF-8 inhibitory activity of this fusion protein has been found to have anti-fibrotic effects, making it a potential therapy for fibrotic diseases. Title: Potential Applications of Taldefgrobep alfa Biosimilar Taldefgrobep alfa Biosimilar has the potential to be used as a therapeutic agent for a wide range of diseases. Its specific targeting of GDF-8 makes it a promising candidate for the treatment of cancers that overexpress this protein. In addition, its ability to inhibit muscle wasting and fibrosis makes it a potential treatment for conditions associated with these pathologies. Moreover, Taldefgrobep alfa Biosimilar can also be used as a research tool to study the role of GDF-8 in various diseases. Its high specificity and potency in inhibiting GDF-8 make it a valuable tool for understanding the mechanisms of GDF-8 signaling and its role in disease progression. Conclusion: In conclusion, Taldefgrobep alfa Biosimilar is a novel fusion protein that has the potential to be used as a therapeutic agent for various diseases. Its unique structure, comprising of a monoclonal antibody and a GDF-8 inhibitor, allows for specific and potent inhibition of GDF-8, a protein involved in several pathological processes. With promising results in pre-clinical studies, Taldefgrobep alfa Biosimilar holds great promise for the treatment of cancer, muscle wasting, and fibrotic diseases. Additionally, its potential as a research tool makes it a valuable asset in the study of GDF-8 signaling and its role in disease.

GDF-8 Antibody (YA4877), MedChemexpress, HY-P85185

GDF-8 Antibody (YA4877) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to GDF-8.

anti-human GDF-8 monoclonal antibody Anti-Human 100 µg, Reliatech, 101-M756

Anti-GDF8 / Myostatin antibody [6E4B2], Abcam, AB201954

This product was changed from ascites to supernatant. Lot no's high than GR285002-6 are from Tissue Culture Supernatant

Human Myostatin (MSTN) ELISA Kit, Abbexa, abx051582

Human Myostatin (MSTN) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human Myostatin concentrations in serum, plasma and other biological fluids.

Chicken Myostatin (MSTN) ELISA Kit, Abbexa, abx150046

Chicken Myostatin (MSTN) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Chicken Myostatin concentrations in serum, plasma, tissue homogenates and other biological fluids. This assay has high sensitivity and excellent specificity for detection of Myostatin (MSTN)No significant cross-reactivity or interference between Myostatin (MSTN) and analogues was observed.

GDF-8/Myostatin Rabbit mAb, ABclonal, A22725